Introduction

This analysis examines the historical and forecast performance for Actelion in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

*Benchmark Actelion's performance against key rivals in the ethical pharmaceutical sector

*Learn how Actelion's focus on a novel pathophysiological pathway has rapidly transformed it from a startup biotech into a billion dollar company

*Evaluate the impressive pipeline potential that is set to drive Actelion's future commercial focus


Report Highlights

[Studien Infos ausblenden]